August 20, 2014

Merck Consumer Care, the makers of Coppertone, and the scientists at the Coppertone Solar Research Center have developed the Coppertone Sport AccuSpray to help prevent overspray.

August 20, 2014

Adult incontinence and urinary bladder control represent one of the more lucrative categories in OTC, but it’s not necessarily the most talked-about category.

August 20, 2014

Merck Consumer Care’s Oxytrol for Women brings women with overactive bladder concerns to the self-care aisle for the first time.

August 6, 2014

The National Advertising Division on Wednesday determined that Chattem can support certain advertising claims for “Nasacort Allergy 24HR,” an over-the-counter allergy relief medication. The claims were challenged by Merck Consumer Care.

July 10, 2014

A wave of new drug introductions and healthcare policy changes has had a significant impact on women’s health care over the past year.

June 20, 2014

Merck announced on Friday that it is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals. On June 9, Merck announced its intent to acquire Idenix.

June 18, 2014

The need state for allergy remedies is significant, according to documents filed by Merck recently in support of its application to switch Singulair. Allergies represent the fifth most-common chronic disease in the United States, impacting 1-in-5 Americans. As many as 90% of allergy sufferers self-treat their condition, and 58% only use an OTC or herbal remedy to relieve their allergy symptoms.

June 18, 2014

There’s a lot happening in the allergy space right now. Chattem’s Nasacort Allergy 24HR recently hit store shelves, and in a little more than 10 weeks on the shelf the nasal corticosteroid has already generated $33.6 million in sales across total U.S. multi-outlets, according to IRI.

June 17, 2014

Merck Consumer Care, the makers of Coppertone, has kicked off its second year of the “Making the Sunscreen Grade” program to help parents teach their children sun-smart behaviors.

June 9, 2014

Merck and Idenix Pharmaceuticals on Monday announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash.

May 16, 2014

These are interesting times to be in the OTC business, Matt Mannelly, Prestige Brands president and CEO, told analysts Thursday.

May 9, 2014

Bayer agreed to acquire the consumer care business of U.S. pharmaceutical company Merck for a purchase price of $14.2 billion. The OTC acquisition will give Bayer the global No. 2 position in nonprescription products following recently announced consolidations in this growing healthcare industry segment, and will significantly enhance Bayer’s business across multiple therapeutic categories and geographies. Merck's consumer care business includes such leading brands as Claritin, Coppertone and Dr. Scholl’s. Pro forma sales of the combined businesses in 2013 amounted to $7.4 billion with Merck’s business contributing approximately $2.2 billion.

Upon completion of the acquisition, Bayer is expected to achieve global leadership positions in dermatology and gastrointestinals and advance to the No. 2 position in the cold, allergy, sinus and flu category. Bayer will remain No. 2 in nutritionals and No. 3 in analgesics. Overall, the proposed GlaxoSmithKline-Novartis combination represents the largest consumer health business with about 5.7% share, according to reports. The Bayer/Merck combination comes in second with around 4.5% share. McNeil Consumer rounds out the top three globally with a share just above 4%.

May 6, 2014

Bayer on Tuesday agreed to acquire the consumer care business of U.S. pharmaceutical company Merck for a purchase price of $14.2 billion.

May 6, 2014

In a related transaction to Tuesday morning's acquisition of Merck's OTC portfolio, Bayer also agreed to enter into a strategic pharma collaboration in the area of cardiovascular diseases with a focus on sGC modulation.

May 6, 2014

The Food and Drug Administration's Nonprescription Drugs Advisory Committee on Friday voted 11-4 opposed to switching Merck's allergy remedy Singulair from Rx-to-OTC, according to an Associated Press report.

May 2, 2014

Bayer is negotiating for Merck's consumer health business in a deal worth $14 billion, according to a Bloomberg report published Friday, citing people with knowledge of the matter.

April 18, 2014

Merck on Thursday announced that the Food and Drug Administration has approved Ragwitek (short ragweed pollen allergen extract) tablet for sublingual use (12 Amb a 1-U).

April 18, 2014

President and CEO of Merck Serono, Belén Garijo, has been appointed an independent director of L'Oréal.

April 15, 2014

The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck's Singulair Allergy tablets.

April 15, 2014

Merck announced that the Food and Drug Administration has approved Grastek (Timothy grass pollen allergen extract) tablet for sublingual use.

April 11, 2014

Ian Read, chairman and CEO of Pfizer, was elected chairman of the Pharmaceutical Research and Manufacturers of America at the trade association’s annual meeting.

March 21, 2014

Danish pharmaceutical group Alk Abello, in association with Merck, expects to start selling its new dust mite allergy tablet in the United States in 2017, according to a Reuters report published Thursday.

March 20, 2014

Members of the board of directors of the Consumer Healthcare Products Association on Wednesday were elected at the association’s Annual Executive Conference at Amelia Island, Fla.

March 10, 2014

Two Rx-to-OTC switches in the past year may serve as a harbinger of what the Food and Drug Administration will consider “switch” worthy.